Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Rhino-Conjunctivitis Overview | 9 | 1 |
| Therapeutics Development | 10 | 1 |
| Pipeline Products for Rhino-Conjunctivitis Overview | 10 | 1 |
| Rhino-Conjunctivitis Therapeutics under Development by Companies | 11 | 1 |
| Rhino-Conjunctivitis Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Rhino-Conjunctivitis Products under Development by Companies | 15 | 2 |
| Rhino-Conjunctivitis Companies Involved in Therapeutics Development | 17 | 13 |
| ALK-Abello A/S | 17 | 1 |
| Allergy Therapeutics Plc | 18 | 1 |
| ASIT biotech s.a. | 19 | 1 |
| Bial - Portela &Ca, S.A. | 20 | 1 |
| Circassia Pharmaceuticals Plc | 21 | 1 |
| Faes Farma, S.A. | 22 | 1 |
| Griffin Discoveries BV | 23 | 1 |
| HAL Allergy BV | 24 | 1 |
| Immunomic Therapeutics, Inc. | 25 | 1 |
| Laboratorios LETI S.L. | 26 | 1 |
| Oxagen Limited | 27 | 1 |
| Roxall Medizin GmbH | 28 | 1 |
| Stallergenes SAS | 29 | 1 |
| Rhino-Conjunctivitis Therapeutics Assessment | 30 | 10 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Combination Products | 31 | 1 |
| Assessment by Target | 32 | 2 |
| Assessment by Mechanism of Action | 34 | 2 |
| Assessment by Route of Administration | 36 | 2 |
| Assessment by Molecule Type | 38 | 2 |
| Drug Profiles | 40 | 40 |
| Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis Drug Profile | 40 | 1 |
| Allergen for Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 41 | 1 |
| Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma Drug Profile | 42 | 1 |
| Allergen for Allergic Rhino-Conjunctivitis Drug Profile | 43 | 2 |
| Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 45 | 1 |
| Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis Drug Profile | 46 | 1 |
| Allergen for Cupressus Arizonica Pollen Induced Allergic Rhino-Conjunctivitis Drug Profile | 47 | 1 |
| Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 48 | 1 |
| Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 49 | 1 |
| Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 50 | 1 |
| Allergen for Salsola Kali Pollen Induced Allergic Rhinoconjunctivitis Drug Profile | 51 | 1 |
| Allergovac Drug Profile | 52 | 1 |
| ASP-4070 Drug Profile | 53 | 3 |
| bilastine Drug Profile | 56 | 2 |
| clustoid wiesenlieschgras Drug Profile | 58 | 1 |
| gp-ASIT Drug Profile | 59 | 2 |
| OC-000459 Drug Profile | 61 | 3 |
| OC-2417 Drug Profile | 64 | 1 |
| Pollinex Quattro Grass Drug Profile | 65 | 3 |
| Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma Drug Profile | 68 | 1 |
| standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine Drug Profile | 69 | 5 |
| Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis Drug Profile | 74 | 2 |
| Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma Drug Profile | 76 | 2 |
| Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis Drug Profile | 78 | 2 |
| Rhino-Conjunctivitis Dormant Projects | 80 | 1 |
| Rhino-Conjunctivitis Discontinued Products | 81 | 1 |
| Rhino-Conjunctivitis Product Development Milestones | 82 | 7 |
| Featured News &Press Releases | 82 | 1 |
| Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study | 82 | 1 |
| Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen | 83 | 1 |
| May 18, 2014: BioTech Tools will be present at the EAACI congress | 84 | 1 |
| Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology | 85 | 1 |
| Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics | 86 | 1 |
| Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites | 87 | 1 |
| Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA | 87 | 1 |
| Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study | 88 | 1 |
| Appendix | 89 | 2 |
| Methodology | 89 | 1 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 89 | 1 |
| Expert Panel Validation | 89 | 1 |
| Contact Us | 89 | 1 |
| Disclaimer | 90 | 1 |